Ann: Positive 8-month Interim Data from OLE Study, page-35

Agree the survival, if attributable, is key.

But if the trend follows, soon we will be in line with other treatment regimes in healey....but having said that we are on average at 20 months treatment.

Considering the healey trials were 6 months, our earlier alsfrs reductions were significantly better in the early periods. At some point people will decline, and unlikely to be linear.

I think however the market in general will see this as not a great update, so some context setting by the team would be useful.

Interesting that some other failed drugs also showed greatly increased survivability.